3.33
-0.23(-6.46%)
Currency In USD
| Previous Close | 3.56 |
| Open | 3.56 |
| Day High | 3.59 |
| Day Low | 3.25 |
| 52-Week High | 3.8 |
| 52-Week Low | 1.14 |
| Volume | 586,862 |
| Average Volume | 901,941 |
| Market Cap | 279.53M |
| PE | -3.54 |
| EPS | -0.94 |
| Moving Average 50 Days | 2.75 |
| Moving Average 200 Days | 2.04 |
| Change | -0.23 |
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
GlobeNewswire Inc.
Nov 15, 2024 1:00 PM GMT
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetas
aTyr Pharma to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Oct 31, 2024 12:00 PM GMT
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announce
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
GlobeNewswire Inc.
Oct 08, 2024 12:00 PM GMT
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetas